16,113 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by Corient Private Wealth LP

Corient Private Wealth LP bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 16,113 shares of the biotechnology company’s stock, valued at approximately $1,313,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ARWR. Carolina Wealth Advisors LLC raised its position in shares of Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares during the last quarter. First Horizon Corp boosted its holdings in Arrowhead Pharmaceuticals by 36.2% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 174 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Arrowhead Pharmaceuticals by 1.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after purchasing an additional 178 shares during the period. Optiver Holding B.V. increased its position in Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the period. Finally, Versant Capital Management Inc raised its holdings in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director Michael Perry sold 11,600 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director directly owned 111,459 shares in the company, valued at $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Adeoye Olukotun sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director directly owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $86.34 on Friday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $27.10 and a twelve month high of $95.49. The stock’s 50 day moving average is $84.11 and its 200-day moving average is $74.31. The firm has a market capitalization of $12.16 billion, a price-to-earnings ratio of -38.37 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business’s revenue for the quarter was up 171.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.26) EPS. Sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ARWR shares. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Stifel Nicolaus initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective for the company. Morgan Stanley lifted their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Chardan Capital reiterated a “buy” rating and set a $115.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, August 31st. Finally, Leerink Partners increased their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.42.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.